STAG2 mutations have previously been grouped with other secondary AML ontogeny-defining mutations [20, 21], and the 2022 European Leukemia Network (ELN) guidelines classify them in the subgroup of adverse risk AML [22]. This evidence concerns the gene STAG2 and acute myeloid leukemia.